Kiromic Biopharma, Inc.: going-concern / distress — Kiromic BioPharma files for Chapter 7 bankruptcy; board and officers depart

Kiromic Biopharma, Inc.

Filed voluntary Chapter 7 bankruptcy petition on March 21, 2025 in Delaware Bankruptcy Court.
Chapter 7 trustee to be appointed to administer and possibly liquidate company assets.
All four board members (Pietro Bersani, Michael Nagel, Mike Catlin, Pamela Misajon) resigned effective immediately.
Terminated CFO Brian Hungerford, COO Leonardo Mirandola, and Chief of Staff Scott Dahlbeck on March 21, 2025.
Board has zero members following resignations; control passes to trustee.

Key facts

Extracted from this filing and checked against the source text.

Distress & Bankruptcy SEC 8-K Item 1.03 confidence 1.0

Kiromic Biopharma, Inc. entered chapter 7 in United States Bankruptcy Court for the District of Delaware (petition 2025-03-21).

Proceeding: chapter 7
Court: United States Bankruptcy Court for the District of Delaware
Petition: 2025-03-21

Exact text from the filing

On March 21, 2025, Kiromic BioPharma, Inc. (the "Company") filed a voluntary petition for relief (the "Bankruptcy Filing") under the provisions of Chapter 7 of Title 11 of the United States Code, 11 U.S.C. §101 et seq. (the "Bankruptcy Code").

View on SEC.gov

Browse all distress & bankruptcy →

Source: SEC EDGAR

accession 0001437749-25-008671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.